Latest Healthcare News

Medical Developments International CEO Brent MacGregor is stepping down after six years, with CFO Anita James taking over as interim CEO from 15 October. The board has begun searching for a permanent successor as MacGregor prepares to return to North America.

Promisia Healthcare has maintained group care occupancy at 96%, above its 95% target, while completing the Chatswood acquisition and preparing to potentially accelerate full ownership of Golden View Village. FY27 underlying EBITDAF guidance of at least $8.0 million remains unchanged for the existing portfolio, with updated guidance due in November.

Anatara Lifesciences will manufacture an approximately 10,000-capsule demonstration batch of its AOC anti-obesity compound after deciding further pre-clinical work and an immediate clinical trial are not required. The company ended September with $551,000 in cash, helped by a $318,402 R&D tax rebate.

Orthocell says Remplir was placed successfully in five complex robotic prostatectomy cases, with no device-related complications reported over approximately 12 months. The preliminary results will guide a larger prospective trial ahead of a planned US expansion for the nerve repair product.

Vitura Health has opened FY2027 with a sharp improvement in EBITDA and lower operating costs, while revenue growth continued across its digital health businesses. The figures are unaudited, and the company still needs to prove that the improvement can survive the wind-down of Bupa-related telehealth volumes.

Acrux says the FDA has confirmed the evidence package required to take its female testosterone spray into Phase III trials for postmenopausal women with HSDD. The agency also indicated the company may apply for three years of data exclusivity if the product reaches submission.

Firebrick Pharma has raised approximately $732,000 from strategic investors, with its Philippines licensing partner investing $631,750 to lift its holding above 10%. The funding will support US retail production, a Singapore product launch and working capital.

Ryman Healthcare’s retirement village resales reached an eight-quarter high in the second quarter, while aged care occupancy climbed to 94%. The operating update also shows new-sales inventory continuing to decline as the company positions for stronger recurring earnings.

Medical Developments International returned to EBIT profitability in FY26 as Penthrox volumes strengthened across Australian hospitals and Europe. The company now faces the less glamorous test of converting regulatory progress into repeatable demand while absorbing weaker Respiratory sales and new amortisation costs.

Genetic Signatures reduced its quarterly operating cash outflow to A$1.0 million after restructuring, while commercial testing began under its Danish hospital contract. The company is also advancing an all-scrip Microba merger, but faces a contested shareholder meeting later this month.

An independent, Rhythm-funded economic model estimates its ColoSTAT blood test could avoid 29,427 public-hospital colonoscopies a year and deliver $72.4 million in net annual hospital savings. The figures strengthen Rhythm’s planned case for Medicare reimbursement, but remain modelled estimates rather than evidence from real-world use.

Vitasora says its remote-care model is now functioning, with estimated September-quarter revenue of US$1.028 million and a September exit rate of about US$17,400 a day. The next test is execution: turning planned Care Coordinator hiring into sustained, reconciled revenue and operational break-even.